SXTC: financial statements from SEC — TradeAlmanac

SXTC

China SXT Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue	2m	2m	2m	3m
Cost of revenue	1m	1m	2m	1m
Gross profit	367,427	553,971	426,271	1m
Selling, general and administrative	3m	3m	6m	6m
Operating expenses	3m	3m	6m	6m
Operating income	−3m	−3m	−6m	−5m
Pre-tax income	−3m	−3m	−6m	−5m
Income tax	—	—	—	328,146
Net income	−3m	−3m	−6m	−6m
Earnings per share	−2.32	−28.58	−177.84	−137.92
Earnings per share, diluted	−2.32	−28.58	−177.84	−137.92
Weighted average shares	1m	108,428	33,372	41,591
Weighted average shares, diluted	1m	108,428	33,372	41,591

Balance sheet

Metric	Aug 18, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash and equivalents	—	18m	12m	17m	16m	13m
Receivables	—	1m	1m	1m	—	—

Cash flow

Metric	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating cash flow	−2m	−2m	−80,757	268,293
Depreciation and amortisation	82,297	203,247	250,162	320,007
Share-based compensation	—	352,100	554,571	2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)